Atossa Therapeutics, INC. (ATOS) — 10-Q Filings

All 10-Q filings from Atossa Therapeutics, INC.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (5)

Atossa Therapeutics' Q3 Loss Widens Amid Soaring R&D Costs — Nov 12, 2025 Risk: high
ATOSSA THERAPEUTICS, INC. reported a net loss of $8.692 million for the three months ended September 30, 2025, an increase from a net loss of $7.230 million in
Atossa Therapeutics Files Q1 2025 10-Q — May 13, 2025 Risk: medium
Atossa Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including assets and liabilities, and p
Atossa Therapeutics Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
Atossa Therapeutics, Inc. filed its Q3 2024 10-Q report on November 12, 2024, detailing its financial performance for the period ending September 30, 2024. The
Atossa Therapeutics Files Q2 2024 10-Q — Aug 12, 2024 Risk: medium
Atossa Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position, including common stock, additional
Atossa Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: medium
ATOSSA THERAPEUTICS, INC. (ATOS) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Atossa Therapeutics, Inc. filed a 10-Q report for the period endi

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX